RWD109 the Burden of R/R DLBCL in Finland: PFS of the First-Line Immunochemotherapy and HCRU of the Patients Diagnosed in 2015–2017 in the Hospital District of Southwest Finland

Outcomes of the first-line immunochemotherapy (1L ICT) in DLBCL are heavily influenced by the patient characteristics. The burden of relapsed/primary refractory (R/R) DLBCL has remained unclear. This study characterized DLBCL patients treated in 1L ICT and evaluated the burden of R/R DLBCL in a real-world setting. Adult patients diagnosed in the Hospital District of Southwest Finland (HDSF) in 2015–2017 were included.